

PRESS RELEASE

August 2, 2010

ALK Acquires Nelco Laboratories

ALK-Abelló announces the purchase of Nelco Laboratories' human allergy immunotherapy business. This acquisition expands ALK's reach to additional Allergy Specialists/Providers. The Veterinary business of Nelco, Nelco Vet, will continue to operate as a separate entity. The transaction has been closed. Terms of the deal were not disclosed.

Nelco Laboratories President April Catanzaro will assist ALK in ensuring a smooth transition.

Jose A. Moreno Toscano, President of ALK-Abelló Inc., stated, "We are very excited to welcome all Nelco customers to ALK, and we look forward to a successful partnership as we work to improve the lives of their allergic patients. Our focus continues to be in providing allergy specialists with quality products and services and driving more patients to specialists for proper diagnosis and treatment of allergic disease.

April Catanzaro, President of Nelco Laboratories, stated, "ALK is a perfect fit for Nelco, and our customers will now be able to enjoy an extended level of products and services. I am excited and look forward to this new journey with ALK.

About ALK

ALK is a research driven, global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy) – a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Further information is available at www.alk-abello.com or www.alk-abello.us

Contact Information:

Dana Rohulich

ALK-Abelló

678-206-6158

dana.rohulich@alk-abello.com